Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug

Shares of Altimmune, Inc. (ALT) jumped 16% in premarket trading on Friday after it reported positive topline results from its Phase 2b IMPACT trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Pemvidutide is a drug that targets both GLP-1 and glucagon receptors and is used to treat liver diseases.

The company said that the 48-week data showed statistically significant improvements versus placebo in key non-invasive liver tests, including enhanced liver fibrosis and liver stiffness, with continued progress from week 24. The higher dose also delivered additional weight loss without signs of plateauing, while maintaining a favorable safety profile.

Altimmune said it held a productive End-of-Phase 2 meeting with the FDA, aligning on plans for a registrational Phase 3 trial.

"These results reinforce that pemvidutide may address both liver-specific and metabolic drivers of MASH without compromising tolerability – three critical elements of a potential effective treatment for this patient population,” said Mazen Noureddin, M.D., IMPACT trial principal investigator, Professor of Medicine at Houston Methodist Hospital and Co-Chairman of the Board for Summit and Pinnacle Clinical Research. 

ALT was the top-trending tickers on Stocktwits at the time of writing.

How Did Stocktwits Users React?

Retail sentiment on Stocktwits shifted to 'bullish' from 'neutral' a day earlier. 

One user said proof that pemvidutide is an effective GLP1/Glucagon agonist continues to grow.

However, another user was bearish on the stock's price movement.

Year-to-date, the stock has declined more than 40%.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on